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Objectives
The contribution of specific antiretroviral drugs to cognitive function in HIV-infected people
remains poorly understood. Efavirenz (EFV) may plausibly cause cognitive impairment. The
objective of this study was therefore to determine whether chronic EFV therapy is a modifier of
neurocognitive and neurometabolic function in the setting of suppressive highly active
antiretroviral therapy.
Methods
We performed an open-label phase IV controlled trial. Adult subjects who were stable on
suppressive EFV therapy for at least 6 months were switched to ritonavir-boosted lopinavir (LPV/r)
with no change in the nucleoside reverse transcriptase inhibitor (NRTI) backbone. The following
parameters were assessed before and 10 weeks after therapy switch: cognitive function (by
CogState computerized battery); brain metabolites (by proton magnetic resonance spectroscopy);
brain activity [by attentional processing task-based functional magnetic resonance imaging]; and
sleep quantity and quality [by sleep diary, Pittsburgh Sleep Quality Index (PSQI) and Epworth
Sleepiness Scale].
Results
Sixteen subjects completed the study. Despite most subjects (81%) self-reporting memory problems
at baseline, cognitive function, brain metabolites, and brain activity showed no change at
10 weeks after switch. Sleep quality improved on switch off EFV [mean PSQI (standard deviation):
EFV, 8.5 (6.5); LPV/r, 5.8 (5.5); mean difference 0.4; 95% confidence interval 6.0 to 0.7].
Conclusions
This is the first study to assess the effects of chronic EFV therapy on neurological function in a
controlled setting. We conclude that EFV withdrawal is unlikely to result in significant
modification of neurocognitive function in otherwise stable HIV-infected people.
Keywords: cognitive impairment, efavirenz, functional magnetic resonance imaging, HIV, magnetic
resonance spectroscopy
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Introduction
Mild cognitive impairment remains common in the highly
active antiretroviral therapy (HAART) era, but the reasons
for this remain incompletely understood [1]. In particular,
the role of specific antiretroviral drugs in mediating cogni-
tive function has received relatively little attention [2].
While it is essential to treat viral replication in the central
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SHORT COMMUNICATION
nervous system (CNS), it is plausible that some antiretrovi-
ral drugs also have adverse effects on neuronal function.
Efavirenz (EFV) remains one of the most commonly used
antiretroviral drugs. It is well recognized that CNS side
effects (especially sleep disturbance) are common in the
first 6 weeks of EFV therapy and sometimes lead to dis-
continuation, but generally subside with continued therapy
[3,4]. Some recent observational studies have suggested
that EFV may additionally be associated with increased
rates of cognitive impairment, a notion that is supported
by some neurotoxicity data from animal and in vitro stud-
ies [5–10]. This hypothesis, however, remains controversial
and has not been confirmed in a controlled trial.
The aim of this study was therefore to determine
whether chronic EFV therapy is a modifier of neurocog-
nitive function in the setting of suppressive HAART.
Methods
Participants
We performed a self-controlled, open-label phase IV pilot
study. Participants were adult patients (aged 18–65 years)
with HIV-1 infection receiving suppressive HAART with
an EFV-containing regimen. All observations were per-
formed at a single study site. Subjects were required to
have a documented HIV-1 RNA viral load (VL) measure-
ment of < 50 HIV-1 RNA copies/ml within the 4 months
preceding study entry and no VL exceeding 200 copies/
ml within 12 months. Subjects were on HAART for at
least 12 months and on EFV for at least 6 months. This
constraint was to ensure that only chronic effects of EFV
were captured. Subjects were ineligible if they had cur-
rent self-reported recreational drug use or weekly alcohol
consumption exceeding 35 units.
All subjects gave written informed consent for participa-
tion in the study. The study was approved by the local
research ethics committee (12/NE/0071), Newcastle-upon-
Tyne Hospitals NHS Foundation Trust R&D approvals com-
mittee (5946), and the UK regulatory authority Medicines &
Healthcare products Regulatory Agency (MHRA) and regis-
tered with the EudraCT trials database (2011-005581-37).
Interventions and measurements
Ritonavir-boosted lopinavir (LPV/r; Kaletra, AbbVie Inc.,
North Chicago, IL, USA; twice daily dosing) was used as a
comparator drug to assess the effects of EFV removal. All
subjects switched from EFV to LPV/r. Participants had
study observations performed at baseline and 10 weeks
after switch. An additional safety monitoring visit was
performed 4 weeks after therapy switch.
A computerized cognitive testing battery (CogState,
CogState Ltd., Melbourne, Australia) was performed com-
prising six tests [listed with abbreviated test name; cogni-
tive domain(s) measured]: Detection (DET; psychomotor
function/speed of processing), Identification (IDN; visual
attention/vigilance), One card learning (OCL; visual learn-
ing and memory), One back (ONB; attention/working
memory), Continuous paired associate learning (CPAL;
visual learning and memory), and Groton maze learning
(GML; executive function/spatial problem solving). Sub-
jects performed a practice run of each test to minimize
training effects. Baseline cognitive impairment was
defined with respect to CogState normative data (ex-
cluding CPAL as sufficient quality data are not currently
available for this test) [11].
Proton magnetic resonance spectroscopy (1H-MRS) was
performed using PRESS (point resolved spectroscopy) vol-
ume selection (TR/TE (repetition time / echo time) = 3 s/
37 ms) on a 3T magnet (Achieva; Philips Medical Sys-
tems, Amsterdam, Netherlands) with ~8 cm3 sampled
voxels in frontal white matter (FWM), frontal grey matter
(FC) and basal ganglia (BG). Metabolite levels of N-acety-
laspartate (NAA), choline (Cho) and creatine (Cre) were
quantified using the QUEST method in JMRUI software
[12]. Concentrations were expressed relative to Cre. NAA
is a widely studied measure of neuronal integrity and is
frequently abnormal in HIV infection. Cho is frequently
altered in inflammation.
Task-based (attentional processing) functional magnetic
resonance imaging (fMRI) assessed response to the Stroop
paradigm using incongruent visual stimuli [13]. The
Stroop test has been shown to be sensitive to psy-
chotropic drug effects including stimulants and sedatives
[14–16], as well as to EFV use in one previous study [5].
fMRI was performed using a gradient-echo EPI (echo pla-
nar imaging) sequence (TR/TE = 1.7 s/30 ms; 27 9
4.0 mm thick slices; 0.5 mm inter-slice gap; 3 mm in-
plane resolution) with a block design Stroop paradigm.
Data were collected in a single fMRI acquisition during
which 360 image volumes were acquired. The stimulus
consisted of a rest period, 18 interleaved blocks of incon-
gruent and neutral stimuli and a final rest period. Subject
responses were monitored using a response box. Analysis
of the fMRI scans was performed using standard process-
ing in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/
spm8/). Analysis was performed for each subject contrast-
ing the incongruent response against the neutral
response. A group analysis was then conducted using
within-subject paired comparison of responses at each
time-point.
Sleep was assessed by means of a 2-week sleep diary,
completion of the Epworth Sleepiness Scale (ESS) (where
© 2017 The Authors HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association HIV Medicine (2017)
2 B Payne et al.
ESS > 10 indicates excessive daytime sleepiness) and
completion of the Pittsburgh Sleep Quality Index (PSQI)
(where PSQI > 5 indicates some level of sleep disturbance
and > 10 indicates significant sleep disturbance) [17,18].
Statistics
As this was a pilot study, a pragmatic sample size was
used [19]. Descriptive statistics and confidence intervals
(CIs) are reported. No data replacement or imputation of
missing data took place.
Results
Seventeen participants were recruited, of whom 16 (three
female and 13 male) completed the study (one subject was
withdrawn at the screening visit). The median age was
50.4 years [interquartile range (IQR) 43.255.7 years]. The
median duration of diagnosed HIV infection was 6.7 years
(IQR: 4.210.0 years). Subjects had been receiving EFV
for a median of 4.5 years (IQR: 4.05.8 years). At baseline,
14 subjects were receiving a backbone of tenofovir/
emtricitabine, and the remaining two subjects were receiv-
ing tenofovir/raltegravir and abacavir/lamivudine, respec-
tively. The median CD4 lymphocyte count at entry was
660 cells/lL (IQR: 536737 cells/lL), and the median
nadir CD4 count was 237 cells/lL (IQR: 37299 cells/lL;
n = 12 subjects with available data for nadir). The median
baseline EFV plasma concentration was 2455 ng/mL (range
818–7197 ng/mL; n = 15 subjects with analysable EFV
levels).
Subjects frequently reported CNS symptoms at both
baseline and follow-up, although the pattern of symp-
toms varied between visits (n = 16): memory problems
(81% of subjects at baseline and 31% at follow-up),
vivid/intrusive dreams (75% and 44%, respectively), fati-
gue (69% and 25%, respectively), concentration difficul-
ties (63% and 75%, respectively), and sleep problems
(56% and 81%, respectively).
Nine subjects (56%) showed evidence of mild cognitive
impairment at baseline [defined as performance > 1 stan-
dard deviation (SD) below age-specific norm (i.e. z-
score < 1) on at least two domains]. Two subjects (13%)
showed severe impairment (z-score < 2 on at least two
domains). No change in cognitive performance was
observed between baseline and follow-up visits. Mean
change score (reported such that a positive change indi-
cates an improvement) for each task was as follows
(n = 16): DET, 0.03 (95% CI: 0.09 to 0.04); IDN, 0.03
(95% CI: 0.02 to 0.07); OCL, 0.03 (95% CI: 0.004 to
0.07); ONB, 0.001 (95% CI: 0.07 to 0.07); CPAL, 13.6
(95% CI: 9.8 to 37.0); GML, 2.9 (95% CI: 3.5 to 9.4).
Summary statistics for cognitive testing are presented in
Table 1.
Subjects were included in paired 1H-MRS analysis
where spectral quality for a given voxel was acceptable
at both study time-points, as follows: FWM, n = 11; FC,
n = 14; BG, n = 8. No changes were observed for any
metabolite in any voxel between baseline and follow-up
visits, with mean change as follows: FC: Cho/Cre, 0.01
(95% CI: 0.01 to 0.02) and NAA/Cre, 0.16 (95% CI:
0.13 to 0.44); FWM: Cho/Cre, 0.03 (95% CI: 0.02 to
0.08) and NAA/Cre, 0.11 (95% CI: 0.12 to 0.33); BG:
Cho/Cre, 0.04 (95% CI: 0.02 to 0.10) and NAA/Cre, 0.03
(95% CI: 0.32 to 0.38). Summary statistics for 1H-MRS
are presented in Table 2.
fMRI data for 14 subjects were analysable. First, the
effects of the ‘Stroop’ task on brain activity were assessed
at the baseline visit to ensure that the fMRI protocol
employed elicited a measureable and expected effect in
our subject group. The analysis assessed activity during
the incongruent stimulus, contrasted against that during
the neutral stimulus. Three clusters of activation during
the task were identified, in an anatomical distribution
corresponding to that expected for this test paradigm:
BA45/BA8/BA46, BA20/BA7/BA40 and BA7 (BA, Brod-
mann’s area; Table S1). Secondly, a comparison was
made of brain activation in response to the incongruent
stimulus between the two study time-points. No change
in brain activation was observed following switch.
There was no overall change in the ESS for patients on
a switch from EFV to LPV/r [mean ESS (SD): EFV, 9.8
Table 1 Neurocognitive testing by the CogState battery
Task n
Baseline (EFV) Follow-up (LPV/r) Change
Mean (SD) Mean (SD) Mean (95% CI)
DET* 16 2.56 (0.08) 2.59 (0.10) 0.03 (0.09, 0.04)
IDN* 16 2.78 (0.07) 2.75 (0.07) 0.03 (0.02, 0.07)
OCL† 16 0.92 (0.11) 0.96 (0.11) 0.03 (0.004, 0.07)
ONB† 16 1.3 (0.13) 1.3 (0.14) 0.001 (0.07, 0.07)
CPAL* 16 121 (46.6) 107.4 (60.1) 13.6 (9.8, 37.0)
GML* 16 62.8 (22.4) 59.8 (24.7) 2.9 (3.5, 9.4)
CI, confidence interval; EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir;
SD, standard deviation.
Detection (DET) and Identification (IDN): speed of performance (mean of
the log10-transformed reaction times for correct responses). One card
learning (OCL) and One back (ONB): accuracy of performance (arcsine
transformation of the proportion of correct responses). Continuous
paired associate learning (CPAL): accuracy of performance (total number
of errors across five rounds). Groton maze learning (GML): total number
of errors made on five consecutive trials at a single session. (Data for
one patient for one task at one visit failed the integrity check. The anal-
ysis was performed with and without inclusion of this data point and
the results were not affected.)
*A lower score indicates a better performance, and change is defined as
baseline score minus follow-up score.
†A higher score indicates a better performance, and change is defined
as follow-up score minus baseline score, so that in all cases a positive
change indicates improvement.
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(5.9); LPV/r, 8.9 (5.1); mean difference 0.9; 95% CI: 2.7
to 0.9]. Sleep diary responses were used to calculate mean
hours of sleep per subject per 24-h period. Fifteen subjects
were included in this analysis. Mean change in mean hours
of sleep between baseline and follow-up visits was 0.1 h
(95% C: 0.7 to 1.0 h). Change in sleep quality (PSQI) was
analysable for 14 subjects. The mean score decreased, indi-
cating an improvement in sleep quality [mean (SD): EFV,
8.5 (6.5); LPV/r, 5.8 (5.5); mean difference 3.4; 95% CI:
6.0 to 0.7]. Of seven patients with a PSQI > 10 (indicat-
ing poor sleep quality) at baseline, four patients had a PSQI
of < 10 at follow-up. No subjects had an insomnia pheno-
type (low ESS < 2 with high PSQI > 10) at either time-
point. As executive function is most typically affected by
sleep disturbance, we assessed the data for any relationship
between baseline sleep quality and GML score. Mean GML
score did not differ in subjects with an abnormal PSQI
score (> 10). Furthermore, there was no association
between baseline EFV plasma concentration and baseline
GML, ESS or PSQI scores or change in these scores after
cessation of EFV.
HIV-1 RNA VL was checked at the safety monitoring visit
4 weeks after treatment switch. At this point, three subjects
(19%) had VL > 50 copies/mL, with values of 69, 107 and
115 copies/mL, respectively. By the follow-up visit, the first
two subjects had re-suppressed to < 50 copies/mL, whereas
the third subject had a VL of 337 copies/mL. Self-reported
adherence was assessed at each of three follow-up visits,
and at each visit four subjects reported at least one missed
dose per week. At baseline, three subjects (19%) reported
diarrhoea (of any severity). Fourteen subjects reported diar-
rhoea at any time following the switch from EFV to LPV/r
(88%) (11 of the 13 not affected at baseline; 85%). There
were no serious adverse events (SAEs) recorded.
Discussion
We have explored the hypothesis that chronic EFV ther-
apy is associated with adverse effects on CNS function.
To our knowledge, this is the first study to assess this
question in a controlled manner by investigating the
effects of a switch away from EFV on neurocognitive
performance, cerebral metabolites, brain activity, and
sleep. Despite the fact that a very high proportion of sub-
jects self-reported CNS symptoms at baseline (including
81% reporting memory problems), we observed no objec-
tive changes in neurocognitive performance across multi-
ple domains, in cerebral metabolites, or in brain activity.
There was, however, an increase in self-reported sleep
quality (PSQI).
This was a pilot study, and so our ability to detect
small effect sizes will have been limited by the sample
size. Notwithstanding this, for almost all parameters stud-
ied, the effect sizes observed were very close to zero, and
there were no consistent trends in directions of change
across related domains (for example in cerebral metabo-
lites or cognitive performance). We therefore conclude
that we are unlikely to have missed any clinically impor-
tant effects.
Given that previous studies have suggested adverse
effects of EFV on neurocognitive function, what are the
possible explanations for our findings? As previous
studies associating cognitive impairment and EFV were
observational and cross-sectional in nature, they were
liable to being confounded by differences between
groups exposed and unexposed to EFV [5]. In the one
randomized controlled trial (RCT) that has compared
EFV and a protease inhibitor, the study was performed
in the setting of treatment-na€ıve subjects starting
HAART [20]. Thus, the predominant effect was changes
in cerebral metabolites associated with suppression of
viral replication and immune reconstitution, and differ-
ences observed between drugs may not have been
wholly independent of their effects on those parameters.
Although most of our subjects did report at least some
CNS symptoms at baseline, those patients who experi-
ence severe early neuropsychiatric side effects of EFV
are likely to switch away from the drug within the first
Table 2 Brain metabolites measured by proton magnetic resonance spectroscopy (1H-MRS)
Baseline (EFV) Follow-up (LPV/r) Change
n Mean SD n Mean SD n Mean 95% CI
FC Cho/Cre 14 0.26 0.03 14 0.27 0.03 14 0.01 0.01, 0.02
NAA/Cre 14 1.8 0.27 14 1.96 0.35 14 0.16 0.13, 0.44
FWM Cho/Cre 13 0.25 0.05 11 0.3 0.07 11 0.03 0.02, 0.08
NAA/Cre 13 1.38 0.33 11 1.51 0.22 11 0.11 0.12, 0.33
BG Cho/Cre 9 0.22 0.09 9 0.23 0.04 8 0.04 0.02, 0.10
NAA/Cre 9 2.34 0.78 9 2.13 0.31 8 0.03 0.32, 0.38
FC, frontal cortex (frontal grey matter); FWM, frontal white matter; BG, basal ganglia; Cho, choline; Cre, creatine; NAA, N-acetylaspartate; CI, confi-
dence interval; EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir; SD, standard deviation.
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few months and therefore would not be represented in
our study. Furthermore, previous EFV switch studies
have documented improvement in CNS symptomatology,
but have not included objective measures of CNS perfor-
mance [21,22]. In theory, a switch off EFV might have
prevented a decline in cognitive function that would
otherwise have occurred, but this seems very unlikely
given the short study period. Alternatively, if LPV/r
were slightly less effective at suppressing viral replica-
tion in the CNS, this could potentially offset any benefits
from EFV withdrawal. We did note some VL blips and
reported missed doses after treatment switch. Again, it
seems unlikely that this would affect CNS function within
the timeframe studied, but this should be explored in future
studies by correlation with cerebrospinal fluid (CSF) HIV
VL. A final possibility is that long-term EFV therapy could
cause a mild but permanent deficit in CNS function (e.g. as
a result of neuronal loss) which would not be reversible
following therapy switch. We did observe around half of
subjects with mild cognitive impairment at baseline, but
this study cannot determine whether this was attributable
to EFV or other factors. This question could only be
explored by a very long follow-up RCT.
In summary, our study did not find support for an
acutely reversible effect of EFV on either CNS metabolites
or cognitive function in otherwise stable patients. These
findings should be confirmed by further randomized
studies.
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